VentureBeat

Spleak Media Network, a content aggregation platform, has added new themes to its portfolio of content communities on the web in partnership with major content publishers.

The company takes news from partnering publishers, such as gossip about Lindsay Lohan, and publishes it across a broad set of internet venues such as instant messaging platforms, social networks, destination web sites and mobile phones. Publishers use the service to expand the reach of their publications to online readers.

The San Francisco company is adding StyleSpleak, TVSpleak, and GameSpleak today, bringing its total number of communities to six. Fans can read, rate, and mash-up the content as they wish.  Spleak previously launched SportSpleak and VoteSpleak in May. CelebSpleak, its first community, launched in November, 2007. That community draws 100,000 visitors every day. The platforms are all interactive. Users can weigh in on topics alongside the professional content.

Major publishers providing content include Hearst Digital Media (CosmoGirl, Seventeen magazine, Teen Magazine, eSpin), DeclareYourself, 18in’08, CBS Sports, Fox Sports, and Yardbarker. Spleak takes about 250 words and splashes it across the different platforms, from MySpace to AIM. It’s a good way for one user to reach a lot of people at once.

Spleak Media Network is venture-backed by Draper Fisher Jurvetson and Sunstone Capital and is privately-held. Competition includes just about any new media news community, such as the live news updates on Twitter or features such as the Facebook Wall. Slide and RockYou also compete to some degree, but Spleak is more focused on pure content.

TODAY’S HEADLINES:

• Gene-silencing developer Santaris raises €20M (PDF release)
• Consumer-driven healthcare manager RedBrick Health prescribed $15M (release)
• Cardiac Dimensions takes in $36M for heart-valve device (release)
• TcLand Expressions gets €8.2M for biomarkers (PDF release)
• TheraQuest Bio gets $3M for pain drugs (release)
• Brain-software maker NeuroTrax visualizes $1.5M (VentureWire)
• ActivBiotics selling off assets after clot-busting drug failure (release)
• Nanostart buys stake in Singapore’s Curiox, a drug-discovery tech firm (release)
• Respiratory biotech Altair Thera gets additional funding (VentureWire)
• Specialty pharma Prometheus Labs files for $100M IPO (Edgar)
• Sirtris co-founder David Sinclair joins Lux Capital as venture partner (PDF release)

Gene-silencing developer Santaris raises €20M — Denmark’s Santaris Pharma, a developer of gene-silencing drugs, raised €20 million ($30 million) (PDF) in a third financing round. Investors included Gilde Healthcare Partners, BankInvest, Novo, LD, Forbion Capital Partners, Global Life Science Venture, Sunstone Capital, Seventure, Omega, Innovation Capital and members of the Company’s board and management. Gilde contributed €7.5 million to the round.

Santaris is pursuing an “antisense” strategy for turning off particular disease-related genes using synthetic strands of nucleic acid, which bind to and deactivate the messenger RNA molecules that are crucial to gene activity. (Technically, the mRNA plays a key role in the manufacture of a gene’s protein or proteins, which in disease states are often either malformed or overproduced. The drug molecule is a complement to the mRNA’s nucleic-acid sequence, which in DNA chemistry makes it an “antisense” molecule.)

Whereas biotechs working on antisense drugs have traditionally used strands of DNA — often chemically modified to improve their durability and cell-penetrating abilities — to block gene activity, Santaris has produced what it claims is a unique RNA analogue that it calls a “locked nucleic acid.” (The company goes into detail here.) The Santaris molecule, which combines LNA and DNA, is supposed to bind RNA in three dimensions, presumably boosting its binding ability and therefore potency.

Santaris is first targeting chronic lymphocytic leukemia, and says its drug candidate has already demonstrated initial safety and efficacy in an early-stage human test. The company has several other candidates in preclinical development, as well as two other molecules it licensed to Enzon Pharmaceuticals, one of which has also begun human testing against cancer.

For a more detailed look at antisense, see our coverage of Excaliard Pharmaceuticals, a biotech that licensed a slew of technology from antisense pioneer Isis Pharmaceuticals, here.

Consumer-driven healthcare manager RedBrick Health prescribed $15M — RedBrick Health, a Minneapolis healthcare company promoting “consumer-oriented” plans that shift much of the financial responsibility for medical care to individuals, raised $15 million in a second funding round. Investors included Fidelity Ventures, Highland Capital Partners and Versant Ventures.

RedBrick aims to help companies set up consumer-directed healthcare plans, which are also known as “defined contribution” schemes in that they limit the financial exposure of employers, who simply make regular contributions to employee “health savings accounts.” These plans, obviously, put the financial onus on individuals, who pay for their own medical care out of these accounts, in contrast to traditional “defined benefit” plans in which individuals pay premiums for comprehensive health coverage. In theory, these consumer-oriented plans should hold down healthcare costs by making individuals more “responsible” users of medical care; in practice, sick patients are often in a terrible position to be good medical “consumers,” and the plans have have proven generally unpopular to boot.

That hasn’t slowed RedBrick or its backers. The company will use the funding to continue expanding its efforts to sell and manage consumer-directed healthcare plans, which RedBrick somewhat misleadingly insists on calling “consumer-owned” healthcare. (Such plans usually couple health-savings accounts with a high-deductible insurance plan.) The company recently announced deals with several new client companies, although none are exactly what you’d call high profile firms — their ranks include the Ridgeview Medical Center in the Minneapolis-St. Paul area, which is switching its employees to a RedBrick-supported plan, and Welch Allyn, a medical-device manufacturer in Skaneateles Falls, N.Y., which is doing likewise.

Cardiac Dimensions takes in $36M for heart-valve device – Cardiac Dimensions, a Kirkland, Wash., developer of heart-valve devices, raised $35.5 million in a fourth financing round. Investors included Johnson & Johnson Development, Lumira Capital, Mitsubishi UFJ Capital, West River Capital, Montgomery & Co., Frazier Healthcare Ventures, Interwest Partners, MPM Capital, and Polaris Venture Partners.

Cardiac Dimensions is working on an implantable device designed to reshape the heart’s mitral valve, which in heart-failure patients sometimes weakens and allows blood to swish backward through the heart’s chambers. We’ve covered several other startups working on mitral-valve devices, including Evalve and Cardiosolutions.